Tracers / [211At]At-astato-benzylguanidine

[211At]At-astato-benzylguanidine

Also written as [At-211]astato-benzylguanidine; [At-211]astatobenzylguanidine; [At-211]At-astatobenzylguanidine

Radionuclide: At-211 t½ 431 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 1

What it is

Compound class: —
Target / mechanism: —
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC	62.6 ± 2.3%	97.8%	Boc2-SGMTB tin precursor	29031230 2018 Nucl Med Biol Astatine-211 in NCS/methanol (30–56 MBq) was added to a vial containing 200 μg of the required tin precursor followed by 10 μL acetic acid. — The radiochemical yield for the synthesis of iso-[211At]SAGMB-Boc2 was 66.8 ± 2.4% (n=7) compared with 62.6 ± 2.3% (n=6) for [211At]SAGMB-Boc2 under identical conditions.

Need this precursor?We can point you to suppliers for [211At]At-astato-benzylguanidine, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.